Relative potency of amiloride and spironolactone in healthy man
暂无分享,去创建一个
[1] R. Perkins,et al. Spironolactone dose-response relationships in healthy subjects. , 1982, British journal of clinical pharmacology.
[2] R. Perkins,et al. Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency. , 1981, British journal of clinical pharmacology.
[3] L. Ramsay,et al. Amiloride, spironolactone, and potassium chloride in thiazide‐treated hypertensive patents , 1980, Clinical pharmacology and therapeutics.
[4] J. Ménard,et al. Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. , 1978, The American journal of medicine.
[5] J. Shelton,et al. Spironolactone and canrenoate‐K: Relative potency at steady state , 1977, Clinical pharmacology and therapeutics.
[6] J. Shelton,et al. Spironolactone and potassium canrenoate in normal man , 1976, Clinical pharmacology and therapeutics.
[7] L. Ramsay,et al. Canrenone--the principal active metabolite of spironolactone? , 1976, British journal of clinical pharmacology.
[8] L. Ramsay,et al. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects. , 1976, British journal of clinical pharmacology.
[9] L. Ramsay,et al. Relative potency of prorenoate and spironolactone in normal man , 1975, Clinical pharmacology and therapeutics.
[10] P. Hessian,et al. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses. , 1975, British journal of clinical pharmacology.
[11] C. Dollery,et al. Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia. , 1973, Lancet.
[12] P. Kincaid‐smith,et al. A new look at the treatment of severe hypertension. , 1973, Clinical science and molecular medicine. Supplement.
[13] R. Burden,et al. The diagnostic and therapeutic value of spironolactone in patients with systemic hypertension. , 1972, Nephron.
[14] A. Struyvenberg,et al. Significance of hypokalaemia due to diuretics. , 1973, The Netherlands journal of medicine.
[15] G. Wilson,et al. Clinical evaluation of amiloride, a potassium‐sparing diuretic , 1969, Clinical pharmacology and therapeutics.
[16] M. Glitzer,et al. N-Amidino-3,5-diamino-6-chloropyrazine-carboxamide : an Active Diuretic in the Carboxamide Series , 1966, Nature.
[17] T. Chalmers,et al. Metabolic studies on the effects of sprinolacton. , 1963, Metabolism: clinical and experimental.
[18] E. Ross. Human assay of electrolyte-active steroids and their antagonists. , 1962, Clinical science.
[19] G. M. Wilson,et al. The action of hydroflumethiazide in relation to adrenal steroids and potassium loss. , 1960, Lancet.
[20] B. B. Johnson. Bioassay of adrenal cortical steroids on the basis of electrolyte excretion by rats: effects of 11-desoxy and 11-oxy-steroids. , 1954, Endocrinology.